Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
JAMA Psychiatry
|
November 5, 2025
Esketamine for Treatment-Resistant Depression-Reply
Adam Janik, Richard C Shelton, Dong-Jing Fu
Polish Journal of Radiology
|
March 29, 2017
Nasal Septal Deviation and Concha Bullosa - Do They Have an Impact on Maxillary Sinus Volumes and Prevalence of Maxillary Sinusitis?
Iwona Kucybała, Konrad Adam Janik, Szymon Ciuk, et al.
Clinical Lung Cancer
|
July 30, 2013
Radiotherapy for stage III non-small-cell lung carcinoma in the elderly (age ≥ 70 years)
Paul D Aridgides, Adam Janik, Jeffrey A Bogart, et al.
Psychological Medicine
|
August 23, 2023
Comments to Drs Taillefer de Laportalière, Jullien, Yrondi, Cestac, and Montastruc
Dong-Jing Fu, Cynthia A Bossie, Rosanne Lane, et al.
The International Journal of Neuropsychopharmacology
|
February 24, 2016
Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
Adam J Savitz, Haiyan Xu, Srihari Gopal, et al.
The International Journal of Neuropsychopharmacology
|
April 10, 2020
Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data
Michel Nijs, Ewa Wajs, Leah Aluisio, et al.
JAMA Psychiatry
|
July 2, 2025
Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial
Adam Janik, Xin Qiu, Rosanne Lane, et al.
Schizophrenia Research
|
October 4, 2015
Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia
Andreas Schreiner, Kaire Aadamsoo, A Carlo Altamura, et al.
CNS Drugs
|
July 8, 2021
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
Richard L Doty, Vanina Popova, Crystal Wylie, et al.
JAMA Psychiatry
|
June 6, 2019
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial
Ella J Daly, Madhukar H Trivedi, Adam Janik, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
JAMA Psychiatry
|
November 5, 2025
Esketamine for Treatment-Resistant Depression-Reply
Adam Janik, Richard C Shelton, Dong-Jing Fu
Polish Journal of Radiology
|
March 29, 2017
Nasal Septal Deviation and Concha Bullosa - Do They Have an Impact on Maxillary Sinus Volumes and Prevalence of Maxillary Sinusitis?
Iwona Kucybała, Konrad Adam Janik, Szymon Ciuk, et al.
Clinical Lung Cancer
|
July 30, 2013
Radiotherapy for stage III non-small-cell lung carcinoma in the elderly (age ≥ 70 years)
Paul D Aridgides, Adam Janik, Jeffrey A Bogart, et al.
Psychological Medicine
|
August 23, 2023
Comments to Drs Taillefer de Laportalière, Jullien, Yrondi, Cestac, and Montastruc
Dong-Jing Fu, Cynthia A Bossie, Rosanne Lane, et al.
The International Journal of Neuropsychopharmacology
|
February 24, 2016
Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
Adam J Savitz, Haiyan Xu, Srihari Gopal, et al.
The International Journal of Neuropsychopharmacology
|
April 10, 2020
Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data
Michel Nijs, Ewa Wajs, Leah Aluisio, et al.
JAMA Psychiatry
|
July 2, 2025
Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial
Adam Janik, Xin Qiu, Rosanne Lane, et al.
Schizophrenia Research
|
October 4, 2015
Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia
Andreas Schreiner, Kaire Aadamsoo, A Carlo Altamura, et al.
CNS Drugs
|
July 8, 2021
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
Richard L Doty, Vanina Popova, Crystal Wylie, et al.
JAMA Psychiatry
|
June 6, 2019
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial
Ella J Daly, Madhukar H Trivedi, Adam Janik, et al.
Page
of 1